At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIVI BioVie Inc
Pre-Market Trading 07-08 05:33:34 EDT
0.4090
-0.0068
-1.64%
High0.4250Low0.4017Vol416.68K
Open0.4250D1 Closing0.4158Amplitude5.60%
Mkt Cap25.00MTradable Cap15.24MTotal Shares61.12M
T/O169.96KT/O Rate1.12%Tradable Shares37.25M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ACCESSWIRE  ·  07-05 21:00
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Despite Hitting US$0.40, BioVie Insiders Still Sold Too Soon
Simply Wall St.  ·  07-01
Despite Hitting US$0.40, BioVie Insiders Still Sold Too Soon
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024
GlobeNewswire  ·  06-25
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024
BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ACCESSWIRE  ·  06-21
BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress
GlobeNewswire  ·  06-20
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26
GlobeNewswire  ·  06-12
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26
BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID
GlobeNewswire  ·  06-04
BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID
BRIEF-Biovie’S Bezisterim Demonstrates Potential Improvements In Sleep/Fatigue And Restless Leg Symptoms For Parkinson’S Disease Patients
Reuters  ·  05-22
BRIEF-Biovie’S Bezisterim Demonstrates Potential Improvements In Sleep/Fatigue And Restless Leg Symptoms For Parkinson’S Disease Patients
BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients
GlobeNewswire  ·  05-22
BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients
BioVie awarded up to $13.1M in funding from U.S. DOD for long COVID treatment
seekingalpha  ·  04-29
BioVie awarded up to $13.1M in funding from U.S. DOD for long COVID treatment
BRIEF-Biovie Awarded About $13.1 Mln From U.S. Defense Department To Evaluate Bezisterim (NE3107)
Reuters  ·  04-29
BRIEF-Biovie Awarded About $13.1 Mln From U.S. Defense Department To Evaluate Bezisterim (NE3107)
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
GlobeNewswire  ·  04-29
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints
GlobeNewswire  ·  04-25
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints
BRIEF-Biovie Inc Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Reuters  ·  04-20
BRIEF-Biovie Inc Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation
GlobeNewswire  ·  04-18
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
StreetInsider  ·  04-12
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
BIOVIE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioVie Inc. and Encourages Investors to Contact the Firm
StreetInsider  ·  03-17
BIOVIE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioVie Inc. and Encourages Investors to Contact the Firm
BIVI DEADLINE ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages BioVie Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 19 Deadline in Securities Class Act
StreetInsider  ·  03-16
BIVI DEADLINE ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages BioVie Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 19 Deadline in Securities Class Act
TUESDAY DEADLINE: Berger Montague Advises BioVie Inc. (NASDAQ: BIVI) Investors to Inquire About a Securities Fraud Class Action by March 19, 2024
StreetInsider  ·  03-14
TUESDAY DEADLINE: Berger Montague Advises BioVie Inc. (NASDAQ: BIVI) Investors to Inquire About a Securities Fraud Class Action by March 19, 2024

Introduction

Company Name.
BioVie Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Issue price:
--